Pathogen-based precision medicine for drug-resistant tuberculosis by Groeschel, Matthias I. et al.
  
 University of Groningen
Pathogen-based precision medicine for drug-resistant tuberculosis
Groeschel, Matthias I.; Walker, Timothy M.; van der Werf, Tjip S.; Lange, Christoph;





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Groeschel, M. I., Walker, T. M., van der Werf, T. S., Lange, C., Niemann, S., & Merker, M. (2018).
Pathogen-based precision medicine for drug-resistant tuberculosis. PLoS Pathogens, 14(10), [1007297].
https://doi.org/10.1371/journal.ppat.1007297
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 13-11-2019
PEARLS
Pathogen-based precision medicine for drug-
resistant tuberculosis
Matthias I. Gro¨schelID1,2*, Timothy M. Walker3, Tjip S. van der WerfID2,
Christoph Lange4,5,6,7, Stefan NiemannID1,7‡, Matthias Merker1‡
1 Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany, 2 Department
of Pulmonary Diseases & Tuberculosis, University Medical Center Groningen, University of Groningen,
Groningen, The Netherlands, 3 Nuffield Department of Medicine, University of Oxford, John Radcliffe
Hospital, Oxford, United Kingdom, 4 Clinical Infectious Diseases, Research Center Borstel, Borstel,
Germany, 5 International Health / Infectious Diseases, University of Lu¨beck, Lu¨beck, Germany,
6 Department of Medicine, Karolinska Institute, Stockholm, Sweden, 7 German Center for Infection
Research (DZIF) Tuberculosis Unit, Borstel, Germany
‡ These authors are joint senior authors on this work.
* mgroeschel@fz-borstel.de
Introduction
The implementation of next generation sequencing techniques, such as whole-genome
sequencing (WGS), in tuberculosis (TB) research has enabled timely, cost-effective, and com-
prehensive insights into the genetic repertoire of the human pathogens of the Mycobacterium
tuberculosis complex (MTBC). WGS data allow for detailed epidemiological analysis based on
genomic distance of the MTBC strains under investigation, e.g., for tracing outbreaks; it can
accelerate diagnostics by predicting drug resistance from a mutation catalogue (Fig 1). Indeed,
specific mutations even permit predictions on the possible clinical treatment course and out-
come [1–4].
These examples of how genomic data inform treatment choice illustrate the concept of pre-
cision medicine in infectious diseases, in which prevention and treatment strategies take infor-
mation from systems biology and individual variability into account [5]. With the increasing
volume of biological and genomic sequence data of pathogens, precision medicine in infec-
tious diseases has gained momentum in recent years.
In this Pearl, we briefly portray how genome sequencing has transformed and accelerated
delivery of tailored treatment to patients with multidrug-resistant (MDR)-TB (defined by in
vitro drug resistance against rifampin and isoniazid) and extensively drug-resistant (XDR)-TB
(defined by MDR-TB plus in vitro drug resistance against a fluoroquinolone and a second-line
injectable drug—amikacin, capreomycin, or kanamycin). We describe its potential to infer
drug resistance profiles and forecast treatment outcomes. Although implementation of person-
alized TB therapy may seem difficult under programmatic conditions, genome-based resis-
tance and outcome prediction are likely to become feasible for this purpose in the near future.
MDR-TB as a model example of precision medicine in infectious
diseases
The emergence of drug-resistant MTBC strains is a major public health challenge. WHO
reports 72% and 65% of MDR-TB among previously treated TB cases in Belarus and the Rus-
sian Federation, respectively [6]. The burdening treatment of MDR-TB/XDR-TB takes much
longer, yielding successful outcome in around 60% in MDR-TB and 35% in XDR-TB patients
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[7,8]. Treatment regimens are empirical from the start—later to be modified as per phenotypic
drug susceptibility test (pDST) results. This process can take several weeks to months due to
slow mycobacterial growth. While classical point-of-care molecular tests, as discussed later,
provide rapid information on selected mutations on few drugs, the treatment already started
may contain ineffective and potentially toxic drugs until pDST results become available [9]. By
leveraging the genomic information of the infecting bacilli, individualized and precise treat-
ment regimens can be tailored to the resistance profile of the infecting microorganism of a par-
ticular patient, instead of using a standardized drug combination. MDR-TB thus serves as a
model example of how the individual variability of the infecting pathogen is taken into account
to deliver faster, precise, and more effective treatment to patients.
Classical molecular test to inform MDR-TB and XDR-TB therapy
The fundamental concept underlying any molecular test is to predict a biological phenotype
based on the genetic mutation or variant detected [10]. These drug resistance-conferring vari-
ants in the genome present reliable biomarkers to predict drug resistance and to design effec-
tive treatment regimens without awaiting culture results. Molecular tests to quickly identify
genotypic drug resistance have been successfully implemented in daily practice [11]. The first
Fig 1. Principle of pathogen-tailored individualized treatment design. (A) Mutations are obtained from a whole-genome sequencing
reference mapping approach that can be also transferred into a cgMLST for molecular outbreak surveillance. (B) Individual mutations are
further interpreted towards their biological phenotype employing a validated consensus mutation catalogue. (C) When canonical and/or high-
level resistance-conferring mutations are present, this drug should not be used. However, mutations associated with a moderate or intermediate
resistance level may allow the use of drugs at increased doses. Moreover, mutations can be used to predict different treatment outcomes. Thus,
by also considering phylogenetic benign mutations that do not confer resistance, a comprehensive molecular drug susceptibility profile could be
inferred for a pathogen-tailored individualized treatment regimen in the future. cgMLST,core genome multilocus sequencing type; TB,
tuberculosis.
https://doi.org/10.1371/journal.ppat.1007297.g001
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molecular assays widely introduced were the line probe assays such as the Genotype
MTBDRplus and MTBDRsl. These qualitative in vitro molecular tests identify the MTBC and
its resistances to key first- and second-line drugs from smear-positive or -negative sputum
specimens, although with reduced accuracy compared to DNA isolates from cultures [12]. The
real-time PCR-based GeneXpert is capable of identifying MTBC DNA as well as rifampin
resistance, mediated by mutations in the rifampin resistance-determining region of the rpoB
gene, as a “close-to-point-of-care-test” with an assay turnaround time of less than two hours.
Yet, all these classical molecular assays are limited because they interrogate only few and con-
fined parts of the genome. Also, they can only be used as rule-in test for drug resistance and do
not infer comprehensive drug susceptibility.
From clinical sample to genome
The advent of WGS in routine microbiological diagnosis allows characterizing all known
genes associated with resistance, providing access to the full “resistome” of bacteria of the
MTBC. In turn, the absence of any known molecular resistance marker for a certain antibiotic
offers the opportunity to predict drug susceptibility, especially for the well-defined first-line
drug targets [13]. Ideally, as with the GeneXpert, the infecting MTBC strain is sequenced
directly from the patient’s sputum, which, however, remains technically challenging [14].
Using targeted DNA enrichment, resistance prediction based on sequenced genomes from
sputum was available within 5 days compared to 36 days from pDST [15]. In this study, the
authors obtained whole genomes (defined as>85% single read coverage against the reference
genome) in 74% of the sputum samples. When capturing only resistance-associated regions,
direct sputum sequencing was obtained within three days of sample receipt [15]. Although this
technique requires refining and simplification for use under service conditions, direct sputum
sequencing can significantly reduce turnaround time to provide comprehensive genotypic
DST results. Another report assessed the turnaround time of sequencing for resistance predic-
tion versus pDST from early-positive Mycobacterial Growth Indicator Tubes that are widely
used as liquid culture for MTBC detection. Results from WGS for first-line drugs were avail-
able within 72 hours of delivery compared to 28 days on average from pDST [16].
Routinely, the genome sequence of the infecting MTBC strain is obtained from high-quality
DNA isolated from cultured organisms. The amount of DNA needed for the sequencing
library preparation is specific for the sequencing platform and chemistry used. Upon align-
ment of the genomic sequence data to a reference TB strain, using bioinformatics software and
algorithms, the recorded variants are reviewed and interpreted. These variants comprise muta-
tions of a single nucleotide, as well as deletions or insertions of multiple nucleotides of the
infecting strain compared to the reference. Management of a routine WGS workflow and the
generated data still requires a dedicated bioinformatics team and server architecture. However,
several commercial (such as Applied Maths Bionumerics, Ridom SeqSphere+) as well as freely
available software packages (such as CASTB, KvarQ, Mykrobe Predictor TB, PhyResSE,
TBProfiler) exist to analyze WGS data with a predefined analysis pipeline and to derive resis-
tance-conferring mutations and lineage classification on the basis of available mutation cata-
logues [17].
From genome to resistance prediction and treatment design
For many of the detected mutations, inconclusive genotype-phenotype correlations render the
analysis challenging. While this association is straightforward for some drugs, it is more intri-
cate for others, e.g., rifabutin, ethambutol, and pyrazinamide [18,19]. On the one hand, clinical
breakpoints to certain antibiotics are significantly higher than the epidemiological cutoff
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(ECOFF), i.e., highest minimum inhibitory concentration (MIC) of a genotypic wild-type
strain. On the other hand, some breakpoints bisect the MIC distribution of mutant strains car-
rying (low-level) resistance-mediating mutations. Both observations likely lead to the report of
false susceptible pDST results and suggest the use of the genotype for resistance to individual
drugs as proxy for phenotypic resistance [19]. Vice versa, currently available mutation cata-
logues likely do not cover the full “resistome” of the MTBC, and high sensitivities to predict
resistance or susceptibility to the major first-line drugs would be desirable for a frontline diag-
nostic test. To fill this gap, global consortia such as CRyPTIC (www.crypticproject.org) and
ReSeqTB (platform.reseqtb.org) have been established to increase the performance of molecu-
lar predictions of drug resistance in TB. Results from the CRyPTIC consortium of>10,000
genomes found high sensitivities to detect resistant phenotypes for all first-line drugs, i.e.,
97.1% for isoniazid, 97.5% for rifampin, 94.6% for ethambutol, and 91.3% for pyrazinamide
[20]. Sensitivity to predict susceptibility to the first-line drugs isoniazid and rifampin was 99%
and 98.8%, respectively [20]. Recently, a genome-wide association study based on 6,465 clinical
TB isolates pointed out several new mutations associated with phenotypic resistance to differ-
ent MDR-TB and/or XDR-TB drugs [21]. In another recent effort using likelihood ratio
thresholds to nominate variants that cause phenotypic resistance with high probability, the
authors were able to sort 286 variants from 20 resistance-conferring genes into a grading sys-
tem comprising three levels—high, moderate, and minimal confidence [13]. In addition,
Yadon and colleagues further provided over 300 resistance mediating mutations in the gene
pncA, which confer pyrazinamide resistance along with a classification of susceptible variants
[22]. Independent clinical studies comparing genomic versus traditional pDST data have
recently confirmed that treatment regimens designed with WGS data are congruent with those
guided by pDST [9,23]. Treatments based on WGS were correctly designed in 93% compared
to pDST in a cohort of 25 MDR-TB and/or XDR-TB patients, and only WGS-based regimens
contained no drug that was tested resistant by pDST [9].
Genome-based resistance or susceptibility predictions will likely enter the routine diagnos-
tic workflow in the near future. Larger studies will settle nonconclusive genotype-phenotype
relations to finally create a work list of highly predictive mutations for clinical use.
From genome to outcome prediction
It is generally accepted that genetic tests should have pDST as gold standard, although certain
pDSTs are known to lack reproducibility due to technical limitations and likely bias the inter-
pretation of some mutations [19]. As a consequence, the real gold standard should be treat-
ment outcome. First clinical data are accumulating, demonstrating how pathogen-based
genetic information provides insights on potential treatment course and outcome. Two retro-
spective studies illustrated that specific codon mutations in the fluoroquinone resistance-con-
ferring gyrA gene were linked to poor treatment outcome in MDR-TB patients [1,2]. The
presence of these gyrAmutations was strongly associated with death or treatment failure after
controlling for host and treatment factors in the cohort. A prospective study with 252 patients
with culture-confirmed MDR-TB confirmed the role of fluoroquinolone resistance in precipi-
tating treatment failure [3]. Mutations in other resistance-conferring genes have also been
shown to impact treatment outcome. Resistance to isoniazid, caused by the specific katG
codon 315 variant but not inhA, was shown to accrete unfavorable outcome [4].
In 2017, England was the first country to implement routine WGS for diagnosis and resis-
tance prediction of MTBC on a national scale [24]. Pioneering WGS at a population level facil-
itates a scenario in which pDST is no longer required for genetically susceptible strains. These
patients can be treated using a first-line regimen, given the well-characterized genotype-
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phenotype link for these drugs. Ultimately, the data generated by this large-scale sequencing
effort will allow us to correlate the presence of resistance-conferring mutations with clinical
outcome.
Outlook and other aspects of personalized therapy for MDR-TB
While genome-based resistance prediction has already been practiced in some TB centers lead-
ing to individualized therapy for patients, additional aspects of personalized therapy will likely
guide treatment in the future. Firstly, therapeutic drug monitoring using dried blood-spots
provides information on the drug level at a certain time point. The physician can modify the
dose accordingly to reduce the chance of emerging resistance and mitigate drug-associated
side effects [25]. Secondly, the development of reliable biomarkers for diagnosis and treatment
monitoring will further personalize treatment. The recent identification of whole-blood—
based host genetic signature comprising four genes that predicts progression to TB is promis-
ing [26]. Finally, insights on the phylogenetic lineage of the individual and infecting MTBC
strain, coupled with their virulence and transmission properties, may inform and further indi-
vidualize the treatment course. Although highly clonal, there is significant genetic diversity
among clinical MTBC strains that translates into relevant biological diversity and versatility of
the tubercle bacilli in their respective in vivo niches. Strains of different MTBC lineages can be
highly distinct in their host tropism and ability to progress from latency to active disease biol-
ogy [27]. Drawing on the geographical distribution and restriction of the different lineages, the
notion emerged that some strains adapted to their local hosts, leading to a treatment paradigm
in which the phylogenetic group of the infecting pathogen needs to be taken into account as a
risk factor [28].
Conclusion
In the absence of horizontal gene transfer, its slow mutation rate, and its highly clonal popula-
tion structure, M. tuberculosis infection is the ideal arena to pioneer pathogen-genome guided
treatment decisions. WGS has the potential to accelerate the time-consuming and cumber-
some diagnosis and resistance profiling of MTBC strains to deliver individualized and effective
treatment regimens in a timely manner. Thorough clinical evaluation of treatment is war-
ranted based on as yet unexplained genotype-phenotype correlations. With population-level
WGS introduced, England antecedes a diagnostic algorithm in which pDST will only be
required in cases of first-line drug resistance in a standardized regimen. Exploiting the entire
potential of WGS, detailed information about the phylogenetic lineage of infecting strains can
inform the clinician on the readiness of the strain to develop further drug resistance. Together,
these innovative approaches in TB treatment herald a new era in treatment of MDR-TB that
will contribute to reducing treatment failure and ongoing transmission.
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